- $914.60m
- $533.92m
Solid Biosciences Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Solid Biosciences Gets FDA IND, Health Canada CTA Nod for First-In-Class Cardiac Gene Therapy CPVT
Brief: Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million
Solid Biosciences Inc expected to post a loss of 56 cents a share - Earnings Preview
Solid Biosciences Inc expected to post a loss of 56 cents a share - Earnings Preview
Gene therapy and vaccine makers fall after FDA names Vinay Prasad as top vaccine official
Gene therapy and vaccine makers fall after FDA names Vinay Prasad as top vaccine official
Newscasts - S&P, Dow finish higher at the end of March madness
U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple
Newscasts - Drugmaker shares sink after key FDA official ousted
Gene therapy makers slide on reports that FDA official Peter Marks resigns
U.S. STOCKS ON THE MOVE-Gold miners, Hut 8, Mr Cooper Group
Drugmakers tumble on reports FDA's top vaccine regulator set to leave (updated)
U.S. STOCKS ON THE MOVE-Gene therapy cos, gold miners, chipmakers
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Gene therapy makers slide on reports that FDA official Peter Marks resigns